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Metallothionein (MT) is a low-molecular-
weight metal-binding protein (Kagi 1991).
MT plays important roles in the detoxication
of heavy metals, in the homeostasis of essen-
tial metals, and in the scavenging of free radi-
cals (Kagi 1991; Klaassen et al. 1999).
Moreover, MT expression can be greatly
increased by exposure to a variety of agents
and physiologic stimuli (Kagi 1991). This
includes a variety of metallic agents that can
activate MT gene expression. There are at
least four mammalian major MT isoforms.
The MT-1 and MT-2 isoforms are most
widely expressed, whereas MT-3 is largely
brain-speciﬁc and MT-4 is located mainly in
stratified squamous epithelia (Cherian et al.
2003; Quaife et al. 1994).
Deﬁciency of MT clearly predisposes ani-
mals to metal intoxication and carcinogenesis.
For example, MT-1/2–double knockout
(MT-null) mice are more sensitive than wild-
type mice to the toxicity of cadmium
(Klaassen et al. 1999), mercury (Yoshida et al.
2004), arsenic (Liu et al. 2000), cisplatin
(Satoh et al. 1997), and zinc and copper
(Park et al. 2001). MT-null mice are also
more susceptible to carcinogenic effects of
lead (Waalkes et al. 2004), cisplatin (Waalkes
et al. 2006), and cadmium (Waalkes MP
et al., unpublished observation). Thus, the
levels of MT appear to be a key factor in
determining sensitivity to toxicity and car-
cinogenicity for various metals.
In humans for reasons that are not fully
understood, there is great individual varia-
tion in MT expression (Allan et al. 2000;
Wu et al. 2000). For example, in one study,
MT protein levels in human liver without
any pathology varied from 0 to 104 μg/g tis-
sue (Sillevis Smitt et al. 1992). Various other
authors have seen similar wide-ranging dis-
crepancies in MT expression in human pop-
ulations (Bem et al. 1988; Onosaka et al.
1986). It also appears that polymorphisms
for human MT-2A gene can significantly
affect MT expression (Kita et al. 2006). On
the basis of these findings, we hypothesize
that individuals with a low ability for
MT expression may be susceptible to metal
toxicity.
MT synthesis can be increased by arseni-
cals in mice or rats (Albores et al. 1992;
Kreppel et al. 1993; Liu et al. 2000). Poor
production of MT, as in MT-null mice, pre-
disposes animals to the hepatotoxicity,
nephrotoxicity, and lethality produced by
inorganic arsenicals (Liu et al. 2000; Park
et al. 2001). MT deﬁciency also can enhance
the genotoxicity of methylated arsenicals (Jia
et al. 2004). It is clear that arsenicals can bind
to various MTs (Ngu and Stillman 2006;
Toyama et al. 2002), including human MTs.
However, little is known about any potential
role of MT in arsenictoxicity in humans. 
The use of MT measurement in readily
accessible tissues, such as blood, as a bio-
marker to predict expression levels of MT in
other tissues has not been established in
humans or rodents, and it is unknown if an
individual poorly expressing MT in one tis-
sue would show poor expression in other tis-
sues. There are also difﬁculties in measuring
very low levels of blood MT protein by the
commonly used MT assays. Thus, in the pre-
sent work, we initially determined whether
blood MT transcripts, as measured by the
highly sensitive and accurate real-time reverse
transcriptase–polymerase chain reaction
(RT-PCR) technique, correlate with tissue
MT levels in rodents. We then examined
MT expression in blood and buccal cells in a
population from Guizhou, China, with clear
dermal signs of chronic arsenicosis and ele-
vated urinary arsenic levels (Liu et al. 2002)
compared with a control population from
the same district. The data provide evidence
that blood MT transcript can be used as a
readily available biomarker for individual
ability to express MT in other tissues and
that arsenicosis patients from Guizhou show
lower expression of MT potentially as a
predisposing factor. 
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BACKGROUND: Because metallothionein (MT) is a metal-binding protein that protects against
metal intoxication, it could be a biomarker for individual sensitivity to metal toxicity. 
OBJECTIVE: We assessed the use of bloodborne MT transcript as a reﬂection of tissue MT levels
and examined the potential role of MT in arsenic toxicity in an environmentally exposed human
population. 
METHOD: Rodents were treated with zinc or nonmetallic MT inducers for 4 days, and the blood
and tissues were collected for MT transcript analysis by real-time reverse transcriptase–polymerase
chain reaction and MT protein determination by the cadmium–hemoglobin assay. Blood and buc-
cal cell samples were collected from arsenicosis patients and healthy subjects residing in Guizhou,
China, and total RNA was isolated for MT transcript analysis. 
RESULTS: There was a positive correlation between blood MT-1 and MT-2 transcripts and corre-
sponding hepatic or renal MT transcript levels in rats and mice. Furthermore, there was a posi-
tive correlation between blood MT-1 and MT-2 transcript and tissue MT protein levels in these
animals. A positive correlation also occurred between human blood MT and buccal cell MT tran-
script levels. MT-1A and MT-2A were the major isoform transcripts in human blood and buccal
cells, and significantly lower MT levels were seen in arsenicosis patients compared with healthy
subjects. 
CONCLUSIONS: Blood MT transcript appears to be a useful biomarker of tissue MT levels.
Arsenicosis patients in Guizhou show signiﬁcantly lower MT transcript levels in blood, which may
have predisposed this population to arsenic intoxication. 
KEY WORDS: arsenicosis patients, biomarker, blood, buccal cells, metallothionein. Environ Health
Perspect 115:1101–1106 (2007). doi:10.1289/ehp.10035 available via http://dx.doi.org/ [Online
18 April 2007]Materials and Methods
Animals and treatment. Fischer 344 male rats
weighing 200–220 g and male CD1 mice
weighing 25–30 g were obtained from
Charles River Laboratories (Wilmington,
MA, USA). Animals were housed in facilities
accredited by the American Association for
the Accreditation of Laboratory Animal Care
at the National Institute of Environmental
Health Sciences (NIEHS) at 20–22°C with a
12-hr light/dark cycle for 1 week before treat-
ment. Animals were allowed free access to
food (Rodent Laboratory Chow #5002;
Ralston Purina Co., St. Louis, MO, USA)
and water. To help create varying levels of
MT expression, groups (n = 4–6) of animals
were given the metallic MT inducer zinc
chloride (50, 100, or 200 mol/kg, sc), two
nonmetallic MT inducers (ethanol, 2.5 g/kg,
ig; or oleanolic acid, 50 mol/kg, sc), or equal
volumes of saline as controls (2 mL/kg, sc) for
consecutive 4 days. Twenty-four hours after
the last dose, animals were killed by carbon
dioxide asphyxiation to collect blood and tis-
sues (liver and kidney). For correlative analy-
sis, the individual data were grouped together
by species (rat or mouse) to provide a wide
range of tissue MT expression after different
treatments. All procedures involving the use
of laboratory animals were reviewed and
approved by the Institutional Animal Care
and Use Committee of the NIEHS. Animals
were treated humanely and with regard for
alleviation of suffering.
Study population and sample collection.
Adult patients were from an area of endemic
arsenic intoxication in Guizhou province
(Liu et al. 2002; Lu et al. 2001) and were
selected for this study on the basis of arsenic
exposure history, including elevated urinary
arsenic excretion, and arsenic-induced skin
lesions (hyperkeratosis, hyperpigmentation,
etc.), as well as other clinical symptomology
of chronic arsenic intoxication (Yang et al.
2005; Zhang et al. 2006; Zhao et al. 2005).
Controls were from the same province and
were selected for an absence of signs or symp-
toms of arsenic intoxication. The arsenicosis
patients are exposed to the burning of high-
arsenic–containing coal for heating and dry-
ing food items and would have a complex
exposure by mixed routes (Liu et al. 2002).
In addition, they would be exposed to other
components of coal. Ethanol use and smok-
ing were not assessed in this group. Venous
blood (0.5–0.7 mL) was collected directly in
a tube containing 0.75 mL Trizol. For buccal
cell collection, the mouth was rinsed with
water, followed by brushing with tooth brush
and rinsing with saline that was then col-
lected into a 50-mL tube. The saline rinse
was then centrifuged to pellet cells, and the
saline was decanted off. Trizol (1 mL) was
added to the pellet and the material was
resuspended, then transferred to a 1.5-mL
tube. For blood cell MT analysis, 48 arseni-
cosis patients (26 males and 22 females) and
48 healthy subjects from the same district
(23 males and 25 females) were selected. For
buccal cell analysis, 44 arsenicosis patients
were compared with 12 healthy subjects.
This study has complied with all applicable
requirements of the U.S. and/or international
regulations (including approval from the
Guizhou Health Department), and human
participants gave written informed consent
before the study. The U.S. portion of this
study was performed under a confidentiality
agreement approved by the Ofﬁce of Human
Subjects Research, National Cancer Institute.
RNA extraction and real-time RT-PCR.
Total RNA was extracted from rodent blood
or tissues, or from human blood or buccal
cells with Trizol reagent (Invitrogen,
Carlsbad, CA, USA), followed by purifica-
tion with RNeasy columns (Qiagen, Valencia,
CA, USA). The purity and quantity of
RNA were determined with an ultraviolet
spectrophotometer (Shimadzu Scientific
Instruments, Columbia, MD, USA) with the
A260/A280 ratio > 1.7. All the RNA isola-
tion procedures were performed at Guiyang
Medical College. Purified RNA was reverse
transcribed with MuLV (murine leukemia
virus) reverse transcriptase and oligo-dT
primers. The forward and reverse primers for
selected genes were designed using Primer
Express software (Applied Biosystems, Foster
City, CA, USA) and are listed in Table 1.
The SYBR Green Master Mix (Applied
Biosystems) was used for real-time RT-PCR
analysis. Differences in gene expression were
calculated using threshold cycle (Ct) values,
which were normalized to β-actin. The basal
level for β-actin expression was consistently
about 21 ± 1.5 Ct in both arsenic-exposed
and normal groups and thus was used as the
housekeeping gene. The arbitrary assigned Ct
value was subtracted for all MT isoforms to
generate their relative expression levels.
MT protein determination. Rodent liver
and kidney were homogenized in 10 mM
Liu et al.
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Table 1. Sequence of primers used in SYBR Green real-time PCR analysis.
Gene symbol Accession no.a Forward Reverse
β-actin (human) X00351 ACTGGAACGGTGAAGGTGACA ATGGCAAGGGACTTCCTGTAAC
MT-1A (human) NM_005946 CTCGAAATGGACCCCAACTG CAGCCCTGGGCACACTTG
MT-2A (human) NM_005953 GTGCCCAAGGCTGCATCT GGTCACGGTCAGGGTTGTACA
MT-3 (human) NM_005954 AGTGCGAGGGATGCAAATG GCCTTTGCACACACAGTCCTT
MT-4 (human) U07807 TCCAGGCCTCATGTGATTCAC CCCTCTTGGCTAGGCACAGT
β-actin (rat) V01217 TCCTCCTGAGCGCAAGTACTCT GCTCAGTAACAGTCCGCCTAGAA
MT-1 (rat) NM_138826 TGTGCCTGAAGTGACGAACAG TTCACATGCTCGGTAGAAAACG
MT-2 (rat) M11794 GGGAACTGGGCAGGAATAACA CAGCCTCAAGCCAGGATGTC
β-actin (mouse) M12481 GGCCAACCGTGAAAAGATGA CAGCCTGGATGGCTACGTACA
MT-1 (mouse) BC027262 AATGTGCCCAGGGCTGTGT GCTGGGTTGGTCCGATACTATT
MT-2 (mouse) NM_008630 TGTGCCTCCGATGGATCCT GCAGCCCTGGGAGCACTT
aFrom the National Center for Biotechnology Information, Entrez Nucleotide Database (http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi).
Figure 1. Correlation analysis of blood transcripts with tissue MT transcripts in rats. (A) Correlation of
blood MT-1 transcript with hepatic MT-1 transcript. (B) Correlation of blood MT-1 transcript with renal
MT-1 transcript. (C) Correlation of blood MT-2 transcript with hepatic MT-2 transcript. (D) Correlation of
blood MT-2 transcript with renal MT-2 transcript. Rats (n = 32) were treated with various MT inducers as
detailed in “Materials and Methods,” and MT transcript levels were quantiﬁed by real-time RT-PCR.
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C DTris–HCl buffer (1:5, wt:vol), followed
by centrifugation at 20,000 × g for 10 min.
MT protein concentrations in the cytosol
were then determined by the cadmium–
hemoglobin assay (Eaton and Toal 1982). 
Statistical analysis. Means and standard
errors for each MT isoform and subgroup
were calculated. Two-way Student’s t-tests
were performed with the level of signiﬁcance
set at p < 0.05. Linear (Pearson) correlations
were used to determine statistical signifi-
cance of correlations between blood MT
transcript and tissue MT transcript or pro-
tein levels. The level of significance was set
at p < 0.05. 
Results
Correlation of blood MT transcript with tis-
sue MT transcript in animals. To determine
whether MT transcript levels in blood would
be reﬂective of MT in other tissues, rats and
mice were treated with various inducers of
MT (zinc, ethanol, oleanolic acid) or saline
for 4 days to create varying MT expression
levels. MT transcript or protein levels were
determined 24 hr after the last treatment.
Individual data were grouped together for
correlative analysis, and correlations were
tested using individual values. The correlation
analysis between blood MT-1 and MT-2
transcript and corresponding liver or kidney
transcript in rats is shown in Figure 1. There
were significant correlations between MT-1
transcript in the blood and in the liver
(Figure 1A; p < 0.001, r = 0.540) and
between blood and the kidney (Figure 1B;
p < 0.002, r = 0.536). Similarly, significant
correlations occurred between MT-2 tran-
script in blood and liver (Figure 1C;
p < 0.001, r = 0.546) and between the blood
and kidney (Figure 1D; p < 0.01, r = 0.519).
Significant correlations between blood MT
transcripts and tissue MT transcripts were also
evident in mice (data not shown)
Correlation of animal tissue MT protein
with MT transcripts. The correlation between
hepatic or renal MT protein levels with con-
cordant MT transcript levels in the respective
tissue in rats is shown in Figure 2. There was
a strong correlation between individual
hepatic MT protein level and hepatic MT-1
transcript (Figure 2A; p < 0.001). Similarly,
renal MT protein levels correlated with renal
MT-1 transcript (Figure 2B; p < 0.001).
Highly significant correlations also occurred
between MT protein and MT-2 transcript
(not shown) in both the liver (p < 0.001,
r = 0.924) and kidney (p < 0.001, r = 0.883).
To be useful as an indicator of individual MT
expression, and thus as a potential biomarker
for sensitivity to metal intoxication, MT
expression measured in a readily accessible
sample (i.e., blood) would have to correlate
with individual tissue protein levels. Thus, the
correlation between liver or kidney MT pro-
tein and blood MT transcript was tested in
rats. The results indicate that a strong correla-
tion occurred between blood MT-1 transcript
levels and hepatic MT protein (Figure 2C;
p < 0.001, r = 0.672), and renal MT protein
(Figure 2D; p < 0.001, r = 0.641). Highly sig-
nificant correlations also occurred between
tissue MT protein and blood MT-2 transcript
in both the liver (p < 0.001) and kidney
(p < 0.001) (data not shown). Thus, it
appears blood MT transcript levels are corre-
lated with tissue MT protein, at least for the
liver and kidney. Significant correlations
between blood MT transcripts and tissue MT
transcript or protein levels were also evident
in mice (data not shown)
MT isoforms in human blood. Human
blood contains transcripts of at least 10 MT
isoforms (Chang et al. 2006; Vandeghinste
et al. 2000). Figure 3 illustrates the relative
transcript levels of MT-1A, MT-2A, MT-3,
and MT-4 in blood of arsenic-intoxicated
patients compared with healthy subjects. The
transcript levels for the major MT isoforms
MT-1A and MT-2A were significantly lower
(p < 0.05) in arsenicosis patients than in
healthy subjects. In addition, regardless of
arsenic exposure, higher levels of MT tran-
scripts were seen with the MT-1A and MT-2A
isoforms relative to other isoforms, whereas
expression ranged from low for MT-4 to barely
detectable for MT-3 in the present study. 
Blood MT isoforms in male and female
subjects. Some evidence indicates there may
be sex-dependent sensitivity to arsenic toxicity
(Ahmad et al. 1999; Liu et al. 2000; Waalkes
et al. 2003) in rodents. Thus, the expression
of major MT isoforms was compared in males
and females (Figure 4). No major differences
in MT-1A and MT-2A isoform expressions
between males and females were evident
either from the normal healthy subjects or
from arsenicosis patients. 
Metallothionein as a biomarker for arsenicosis
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Figure 2. Correlation analysis of (A) hepatic MT protein with hepatic MT-1 mRNA levels; (B), renal MT pro-
tein with renal MT-1 mRNA levels; (C) hepatic MT protein with blood MT-1 mRNA levels; and (D) renal MT
protein with blood MT-1 mRNA levels. Rats (n = 32) were treated with various MT inducers as detailed in
“Materials and Methods”; MT transcript levels were quantiﬁed by real-time RT-PCR, and MT protein was
determined by the cadmium–hemoglobin assay.
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Figure 3. The expression of human MT isoforms in
blood cells of arsenic-exposed patients (n = 48)
and healthy subjects (n = 48) in Guizhou, China.
Total RNA was extracted, purified, reverse-tran-
scripted, and subjected to SYBR Green real-time
quantitative RT-PCR with MT isoform primers. Data
are mean ± SE. 
*Signiﬁcantly different from healthy controls at p < 0.05.
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Figure 4. The sex difference in human MT-1A and
MT-2A expression in blood cells of arsenicosis
patients (26 males and 22 females) and healthy
subjects (23 males and 25 females) in Guizhou,
China. Total RNA was extracted, puriﬁed, reverse-
transcripted, and subjected to SYBR Green real-
time quantitative RT-PCR with MT isoform primers.
Data are mean ± SE. 
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Normal Normal Arsenicosis ArsenicosisMT isoforms in human buccal cells. MT
expression in human buccal cells has not been
previously reported. In the present study
(Figure 5), as with transcript in blood, the
MT-1A and MT-2A isoforms in the buccal
cells were predominant. The expressions of
MT-3 and  MT-4 isoforms were low.
Consistent with blood transcript levels, the
relative expressions of MT-1A and MT-2A
were signiﬁcantly lower in arsenicosis patients
than in healthy subjects. The expressions of
MT-3 and MT-4 isoforms were too low for
valid comparison.
Correlation of human MT transcript in
blood and buccal cells. Human MT-1A and
MT-2A transcript levels in blood and buccal
cells from 36 human subjects were used for
correlation analysis (Figure 6). There was a
highly signiﬁcant correlation between individ-
ual blood MT-1A transcript and buccal cell
MT-1A transcript levels (Figure 6A; p < 0.01,
r = 0.487). Similarly, individual blood
MT-2A transcript was strongly correlated
(p < 0.01, r = 0.434) with buccal cell MT-2A
(Figure 6B). 
Discussion
The present study demonstrates the potential
utility of blood MT transcripts as a biomarker
for tissue MT levels in rodents and in
humans. A clear correlation between blood
MT transcript levels and hepatic and renal
MT transcripts is evident in rats and mice,
and a clear correlation of blood MT tran-
scripts with tissue MT protein levels is also
evident in these animals. Furthermore, there
is a correlation between human blood and
buccal cell MT transcript levels in humans.
Thus, blood MT transcripts appear to be a
useful biomarker for target tissue MT levels.
In arsenicosis patients, distinctly lower
levels of blood MT isoform transcripts were
consistently observed. The transcript levels of
MT isoforms in buccal cells of arsenicosis
patients were also signiﬁcantly lower than in
healthy subjects. For example, the major iso-
forms of MT-1A and MT-2A transcript levels
in arsenicosis patients were at least 65%
(blood) and 74% (buccal cells) lower than
that in control. These MT isoform levels were
independent of sex. There are several factors
that may be the basis for the lower MT
expression seen in the arsenicosis patients in
the present study. First, lower MT expression
may have been a predisposing factor to
arsenic toxicity. In this regard, not all people
living in this area of endemic arsenicosis show
overt signs of arsenic intoxication (Liu et al.
2002; Yang et al. 2006; Zhang et al. 2006), so
some differences in sensitivity might be
expected. Differences between the control
population and the arsenicosis population
could contribute variation in MT, and, for
example, smoking and/or ethanol consump-
tion were not assessed in the present study.
Both ethanol and cigarette smoke condensate
will increase MT expression in animals or in
cultured cells (Chen et al. 2005; Klaassen
et al. 1999). Finally, the arsenicosis patients
are also exposed to various components of
coal combustion, and this may have altered
MT expression. Thus, there are various fac-
tors that may have contributed to the ﬁnding
of low MT in association with human arseni-
cosis, and further work will be required to
deﬁne it as a predispositional factor.
Erythrocytes in the blood appear unable
to synthesize proteins, including MT, and
thus MT transcript in the blood likely comes
from monocytes and lymphocytes (Koizumi
et al. 1987) or cellular turnover of internal tis-
sues. In rodents, proerythroblasts have been
hypothesized as the site of MT biosynthesis,
which may contribute to MT present in
mature erythrocytes (Tanaka et al. 1985). In
any event, the commonly used cadmium–
hemoglobin assay is unable to reliably detect
MT protein in the blood, probably because of
abundant sample hemoglobin and interfer-
ence by other blood components. Thus, iso-
lated leukocytes have been used to evaluate
MT production after in vitro exposure to vari-
ous MT inducers (Allan et al. 2000; Yurkow
and DeCoste 1999) but have not been used
to evaluate MT in other tissues. The results of
the present study clearly indicate that blood
MT transcript are predictive of tissue MT
gene expression in rodents, and human blood
MT transcript levels are correlated with buc-
cal cell MT transcript levels in the present
study. Thus, blood MT transcript determina-
tions could provide insight into MT levels in
human tissues and could be used to identify
susceptible populations.
In animal studies, arsenic effectively acti-
vates MT gene expression (Albores et al.
1992; Kreppel et al. 1993; Liu et al. 2000).
The induction of MT by arsenicals can be
envisioned, at least in part, as an adaptive
response to overcome toxic insult from this
metalloid. For example, MT-null mice are
more clearly sensitive than wild-type mice to
arsenic-induced acute lethality (Park et al.
2001) and chronic hepatotoxicity or nephro-
toxicity (Liu et al. 2000). In addition, poor
production of MT makes mice more suscepti-
ble to dimethylarsinic acid–induced DNA
strand breaks in peripheral blood cells (Jia
et al. 2004). These data support a protective
role of MT against arsenical toxicity, at least
in part, by binding arsenic to MT and thus
sequestering arsenic from critical cellular
organelles (Ngu and Stillman 2006; Toyama
et al. 2002). MT-null mice were more suscep-
tible to carcinogenic effects of other metal
compounds such as lead and cisplatin
(Waalkes et al. 2004, 2006). Therefore, tissue
MT levels in rodents appear to dictate the
sensitivity to arsenic intoxication, with lower
levels enhancing susceptibility. It is notewor-
thy that MT levels were low in the arsenic-
exposed population studied in the present
work even though arsenic can effectively acti-
vate MT synthesis (Albores et al. 1992;
Kreppel et al. 1993; Liu et al. 2000). Thus,
one valid interpretation of these human data
is that poor MT expression may have predis-
posed these patients from Guizhou to arsenic
intoxication. It is important to note that
although individuals can be exposed to similar
arsenic levels, the symptoms of arsenic intoxi-
cation can vary widely in the population from
Guizhou (Liu et al. 2002; Yang et al. 2005;
Zhao et al. 2005; Zhou et al. 2000), and the
present group was selected based on overt
evidence of arsenicosis.
Although MT can be induced easily by a
variety of stimuli, low MT expression has
also been reported in a variety of tumors
(Jacob et al. 2002). For example, poor MT
expression occurs with human and murine
Liu et al.
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Figure 6. Correlation analysis of MT-1A (A) and
MT-2A (B) expression between blood cells and
buccal cells of arsenicosis patients from Guizhou,
China (n = 36). Sample collection and MT determi-
nation by real-time RT-PCR are described in detail
in “Materials and Methods.”
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hepatocellular tumors compared with tumor-
surrounding tissues (Lu et al. 2003; Waalkes
et al. 1996). Relative expression of MT is,
however, dependent on the type of tumor,
tissue, and stage of the disease (Cherian et al.
2003; Jin et al. 2004). For example, many
human tumors show relatively high expres-
sion of MT. So it does not appear that sup-
pression of MT expression is a general
characteristic of oncogenesis or carcinogen
exposure. In our recent transplacental arsenic
carcinogenesis studies, hepatic MT was ini-
tially increased immediately after arsenic
exposure ended on gestation day 18 and at
birth, but by 104 weeks of age, the expres-
sion of MT in arsenic-induced liver tumors
or in normal surrounding liver is only half
that of the controls (Liu et al. 2006). This
might indicate that there was an initial MT
induction by arsenic that was lost when
arsenic exposure was discontinued. Not all
arsenic-treated mice developed tumors
(Waalkes et al. 2003), and MT expression
was not assessed in mice without arsenic-
induced tumors. In any event, the decreased
MT expression in blood and buccal cells of
the arsenicosis patients in the present study
occurred during continuous exposure to
arsenic, and the data indicating arsenic can
induce MT (Albores et al. 1992; Kreppel
et al. 1993; Liu et al. 2000) make it difﬁcult
to envision reduced MT as an effect of
arsenic exposure. Expression polymorphism
of MT exists in humans (Kita et al. 2006;
Wu et al. 2000) that could potentially predis-
pose populations to arsenic toxicity and car-
cinogenesis. Further work is required to
deﬁne the role of MT in arsenic toxicity and
carcinogenicity. 
Low expression of MT in arsenicosis
patients could also be due to alterations in cell
proliferation, or cell differentiation, such as
the events seen during tumor progression
(Cherian et al. 2003), or due to indirect
methylation of the MT genes (Jacob et al.
2002). MT gene hypermethylation is associ-
ated with reduced expression in various
human or rodent tissues and cells (Compere
and Palmiter 1983; Deng et al. 2003; Huang
et al. 2003; Jacob et al. 2002). Chemical or
physical alterations in MT gene methylation
significantly alter expression potential
(Compere and Palmiter 1983; Huang et al.
2003; Jacob et al. 2002). Whether the
decreased MT isoform expression in blood
and buccal cells of arsenic-exposed patients is
associated with differences in MT gene
methylation warrants further investigation. 
This study demonstrated for the ﬁrst time
that the expression of MT isoforms can be
analyzed in buccal cells, and that the results
from buccal cells were consistent with blood
samples. Buccal cells have been used to detect
arsenic-induced DNA damage (micronuclei
assay and apoptosis) in arsenic-exposed popu-
lations from Inner Mongolia, China (Tian
et al. 2001), and from Chile (Martinez et al.
2005). The collection of buccal cells is more
practical for examining arsenic-induced aber-
rant gene expression than most other tissues.
In this regard, the buccal cell gene expression
analysis of the same arsenic-exposed popula-
tion from Guizhou found increased TP53
gene expression, but no alterations in α-feto-
protein expression (Yang et al. 2005). Thus,
gene expression analysis with buccal cells
could have potential use as a noninvasive
measure of arsenic-induced aberrant gene
expression and toxicity. 
In summary, the current study indicates
blood MT expression is indicative of tissue
MT expression in rats and mice and that poor
expression of MT in blood and buccal cells is
associated with arsenicosis in humans.
Limited production of MT could be a suscep-
tiblity factor in arsenic toxicity, and, perhaps,
arsenic carcinogenesis. 
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